AIM ImmunoTech Inc. (NYSEAMERICAN:AIM) Short Interest Update

AIM ImmunoTech Inc. (NYSEAMERICAN:AIM) was the recipient of a significant increase in short interest in the month of January. As of January 30th, there was short interest totaling 328,268 shares, an increase of 429.9% from the January 15th total of 61,954 shares. Currently, 10.0% of the shares of the company are sold short. Based on an average trading volume of 114,674 shares, the short-interest ratio is presently 2.9 days. Based on an average trading volume of 114,674 shares, the short-interest ratio is presently 2.9 days. Currently, 10.0% of the shares of the company are sold short.

AIM ImmunoTech Stock Performance

NYSEAMERICAN AIM traded down $0.05 during trading hours on Thursday, reaching $0.79. The company’s stock had a trading volume of 384,505 shares, compared to its average volume of 3,686,159. The company’s 50-day moving average is $1.25 and its two-hundred day moving average is $1.99. AIM ImmunoTech has a fifty-two week low of $0.77 and a fifty-two week high of $36.00. The stock has a market cap of $2.59 million, a PE ratio of -0.04 and a beta of 1.26.

AIM ImmunoTech (NYSEAMERICAN:AIM) last posted its quarterly earnings data on Monday, November 17th. The company reported ($1.57) EPS for the quarter. The company had revenue of $0.03 million during the quarter. Equities analysts expect that AIM ImmunoTech will post -0.3 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of AIM. DRW Securities LLC lifted its holdings in shares of AIM ImmunoTech by 60.6% during the 4th quarter. DRW Securities LLC now owns 69,545 shares of the company’s stock worth $79,000 after acquiring an additional 26,254 shares during the period. Sabby Management LLC purchased a new stake in AIM ImmunoTech in the third quarter valued at approximately $79,000. Finally, Corient Private Wealth LLC acquired a new position in AIM ImmunoTech during the second quarter worth approximately $87,000. Institutional investors and hedge funds own 12.02% of the company’s stock.

Analyst Ratings Changes

Separately, Zacks Research lowered AIM ImmunoTech from a “strong-buy” rating to a “hold” rating in a report on Friday, February 6th. One analyst has rated the stock with a Strong Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat.com, AIM ImmunoTech presently has a consensus rating of “Buy”.

AIM ImmunoTech Company Profile

AIM ImmunoTech is a clinical-stage biotechnology company focused on the development and commercialization of immune-modulating therapies for the treatment of viral infections and cancer. The company’s lead product candidate, Ampligen (rintatolimod), is a proprietary toll-like receptor 3 (TLR3) agonist that aims to enhance the body’s innate immune response. AIM ImmunoTech’s research and development efforts center on demonstrating the safety and efficacy of Ampligen as both a standalone therapy and in combination with other treatments.

In addition to its oncology and antiviral programs, the company is advancing clinical trials of Ampligen in patients with chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) and exploring potential applications for emerging viral threats.